Literature DB >> 29188315

High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin's lymphoma in China.

Chaoyu Wang1, Bing Xia1, Qiaoyang Ning1, Haifeng Zhao1, Hongliang Yang1, Zhigang Zhao1, Xiaofang Wang1, Yafei Wang1, Yong Yu1, Yizhuo Zhang2.   

Abstract

We retrospectively analyzed a large study to investigate the association of hepatitis B virus (HBV) with aggressive B cell non-Hodgkin's lymphoma (aggressive B-NHL) in China, where HBV is endemic. HBV was present in 39 aggressive B-NHL patients (10.46%), 13 indolent B-NHL patients (5.09%), 12 multiple myeloma (MM) patients (3.67%), and 5 solitary plasmacytoma (SP) patients (6.67%). HBV infection was significantly associated with increased risks for aggressive B-NHL (P < 0.01). HBV seems to have a very important role in the pathogenesis of aggressive B-NHL in China.

Entities:  

Keywords:  Aggressive B cell non-Hodgkin’s lymphoma; Hepatitis B virus; Indolent B cell non-Hodgkin’s lymphoma; Multiple myeloma; Solitary plasmacytoma

Mesh：

Year:  2017        PMID： 29188315     DOI： 10.1007/s00277-017-3188-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  8 in total

1.  Tumor-associated macrophages increase the proportion of cancer stem cells in lymphoma by secreting pleiotrophin.

Authors:  Xia Wei; Sainan Yang; Xin Pu; Silian He; Zailin Yang; Xiaomin Sheng; Xiaoqin Meng; Xue Chen; Ling Jin; Wen Chen; Yong Zhang
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

2.  Epstein-Barr virus positive diffuse large B-cell lymphoma transformed into angioimmunoblastic T-cell lymphoma after treatment.

Authors:  Chaoyu Wang; Yi Gong; Qingming Jiang; Xiping Liang; Rui Chen
Journal:  Clin Case Rep       Date:  2021-05-05

3.  [The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-06-14

4.  Hepatitis B virus infection among oncohematologic disease patients in Central Brazil: prevalence, risk factors and immunization.

Authors:  Grécia C Pessoni; Tássia A Marinho; Megmar M Santos Carneiro; Regina M Martins; Caroline C Soares; Leandro N Silva; Marcia A Matos; Adriano M Arantes; Juliana A Teles; Nathalia C Santos; Sheila Araujo Teles
Journal:  Hematol Transfus Cell Ther       Date:  2019-03-28

5.  Establishment and characterization of HBV-associated B lymphocytes with an immortalization potential.

Authors:  Xiaoying Qi; Xien Gui; Ke Zhuang
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

Review 6.  Progress in the Treatment of HIV-Associated Lymphoma When Combined With the Antiretroviral Therapies.

Authors:  Chaoyu Wang; Jun Liu; Yao Liu
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

7.  Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study.

Authors:  Yung-Rung Lai; Ya-Lan Chang; Chiu-Hsiang Lee; Tung-Han Tsai; Kuang-Hua Huang; Chien-Ying Lee
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

8.  Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report.

Authors:  Xuzhao Zhang; Yun Liang; Xian Li; Weiqin Wang; Jiefeng Tong; Yang Xu
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.